Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch + Lomb Corporation filings document the reporting obligations of a Canada-incorporated eye health company whose common shares trade on the New York Stock Exchange and Toronto Stock Exchange under BLCO. Its 8-K reports cover quarterly and annual operating results, non-GAAP financial measures, guidance, investor presentations, material credit-agreement amendments and refinancing activity.
Proxy materials describe annual shareholder meeting matters, board composition, director independence, committee assignments and executive compensation governance. Other event filings record board appointments, committee changes, registered common-share details and Regulation FD disclosures tied to the company's product pipeline, Pharmaceuticals, Surgical and Vision Care operations.
Bausch & Lomb Corp reported that President, Surgical, Luc Bonnefoy acquired 30,373 common shares through a grant of restricted share units (RSUs) at no cost per share. These RSUs vest one-third on each of the first three anniversaries of the grant date. After this award, Bonnefoy holds 117,937 common shares directly.
Bausch & Lomb Corp reported that executive Andrew J. Stewart, President, GPIC, acquired 32,710 common shares on February 25, 2026 through a grant of restricted share units (RSUs) at $0.00 per share. After this award, he holds 95,640 common shares directly.
The RSUs vest in three equal installments on each of the first three anniversaries of the grant date, generally contingent on his continued service. Once vested, these RSUs will be settled in Bausch & Lomb common shares.
Hashad Yehia reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp executive Yehia Hashad, EVP of R&D and CMO, received a grant of 35,046 restricted share units (RSUs) on common shares at a price of $0.00 per share. After this equity award, his directly held common shares total 198,906.
The RSUs were granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan and are scheduled to vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service and plan terms. Vested RSUs will be settled in common shares of Bausch & Lomb.
Bausch & Lomb Corp reported that EVP & Chief Legal Officer A. Robert D. Bailey acquired an equity award of 52,570 restricted share units (RSUs) on common shares at a stated price of $0.00 per share. These RSUs were granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
The RSUs are scheduled to vest one-third on each of the first three anniversaries of the grant date, generally requiring Mr. Bailey’s continued service. After this award, his direct holdings in common shares total 223,146 shares, highlighting ongoing stock-based compensation tied to long-term service.
Bausch & Lomb Corp reported that EVP and CFO Sam Eldessouky acquired 81,775 common shares through a grant of restricted share units (RSUs) at a price of $0.00 per share. After this award, he directly holds 473,169 common shares.
The RSUs were granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. They are scheduled to vest in three equal installments on each of the first three anniversaries of the grant date, generally requiring his continued service. Once vested, the RSUs will be settled in common shares of Bausch & Lomb Corporation.
SAUNDERS BRENT L reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp CEO and chairman Brent L. Saunders received an equity grant of 327,102 restricted share units under the company’s 2022 Omnibus Incentive Plan. These RSUs vest in three equal annual installments and settle in common shares upon vesting. After this award, he holds 998,583 common shares directly.
Bausch & Lomb Corp CEO and Chairman Brent L. Saunders reported a tax-related share disposition. On February 23, 2026, 65,444 common shares at $17.99 per share were withheld to cover tax obligations upon vesting of restricted share units. After this withholding, Saunders beneficially owned 671,481 common shares directly.
Bausch & Lomb director Steven H. Collis reported two transactions in common shares. He made an open-market purchase of 15,000 shares at a weighted average price of $17.81 per share, increasing his direct holdings. He also received 4,491 matching restricted share units (MRSUs) granted under the company’s matching share program, tied to this purchase. One-third of these MRSUs will vest on each of the first, second, and third anniversaries of the grant, subject to his continued service. Following these transactions, he directly owned 24,746 common shares.
Bausch & Lomb director Russel C. Robertson increased his stake in the company through both a purchase and an equity award. He bought 4,400 common shares in an open-market transaction at $17.90 per share. On the same date, he also acquired 4,400 matching restricted share units at no cost under the company’s matching share program.
Following these transactions, his direct holdings rose to 76,807 common shares. The matching restricted share units will vest in three equal installments on the first, second, and third anniversaries of the grant date, as long as he continues to serve, except in limited circumstances.
Bausch & Lomb Corp director Karen Ling reported new purchases and awards of common shares. On February 19, 2026, she made an open-market purchase of 4,000 common shares at a weighted average price of $17.742 per share, with individual trades ranging from $17.71 to $17.75. She also acquired 4,000 matching restricted share units in connection with this purchase under the company’s matching share program, which vest in three equal annual installments starting one year after the grant date, subject to continued service.